Flu be gone!

Two new anti-flu drugs just hit the market and will be backed by millions in advertising. But do they work?

Topics: Drugs, Advertising,

Flu be gone!

It’s easy to recognize the familiar signs and sensations of flu season — the hacking cough, the jackhammer headache, the mind-melting fever and the empty office cubicles. But this year there’s a new seasonal symptom — advertising.

Two pharmaceutical giants, Glaxo Wellcome and Roche, are launching massive campaigns to get Americans to shell out millions for new anti-flu remedies. But some of the scientists who have examined the drugs are skeptical they will do much more than fatten drug industry profits.

Each year from November to April, the influenza virus sickens up to 50 million Americans. As common infectious diseases go, it’s a bad one. Healthy adults need about a week to emerge from the flu’s boggy grip, and it kills about 20,000 sickly and elderly Americans each winter. Flu is also an enemy of the state in that it undercuts our efficiency — costing $5 billion in lost work and hospital bills each season, according to the CDC.

Influenza’s evolutionary strategy makes it easy to anthropomorphize as a Bill Gates among bugs — brilliant, devious and sinister. There are dozens of varieties of flu and they mutate faster than Dennis Rodman’s hair. Now and again, the molecular roulette wheel brings forth a pandemic strain unrecognizable to human immune systems; the worst of these was the 1918 virus that killed half a million Americans and 20 million souls worldwide.

Flu shots can be more or less effective protection, depending on whether the scientists who prepare the year’s batch of vaccine correctly predict which strains will predominate in the population. The Clinton administration has advocated inoculation religiously, and this year 90 million Americans are expected to bare arms for the shot — compared with 20 million a year ago.

But until now, once you got the flu the only recourse was to stay in bed with a wet washcloth and a cheesy novel nearby. This year, what passes for a cure has found its way to the market.

The new medications, Glaxo Wellcome’s Relenza and Roche’s Tamiflu, are the first in a class of drugs called neurominidase inhibitors. They work by neutralizing proteins on the viral surface that help the bug emerge from lung cells to replicate. If you haven’t heard of Relenza and Tamiflu, $50 million says you will soon — the two companies are estimated to be spending that amount to promote their drugs.



Obviously $50 million buys a lot of hype, and depending on how you look
at it, hype may be the biggest ingredient in these drugs, which cost about $50 each for a five-day therapeutic course.

Glaxo’s TV ads, produced by Saatchi and Saatchi, started airing last week. They star fat, obnoxious Wayne Knight (Newman from “Seinfeld”) as the flu — an unwanted guest who arrives at your house by bus.

The ad is intended to produce a vaguely uneasy feeling and send you reaching for the phone to get your doctor to write out a prophylactic prescription. But examining Relenza’s trek through the regulatory system produces an equally queasy feeling, akin to seeing an important public figure unclothed — an emperor, say, or perhaps Wayne Knight himself.

Consider this: The British and French medical establishments have
already rejected Relenza as an essentially worthless drug. Despite much gnashing of the teeth by Glaxo Wellcome executives, who accused the British government of trying to destroy the country’s pharmaceutical industry, Britain’s National Institute of Clinical Excellence voted last month against including Relenza on the National Health Service’s formulary.

In February, an expert panel asked by the FDA to offer a verdict on whether it should approve Relenza came to essentially the same decision as the French and British doctors.
“I wasn’t convinced by the data,” says Edwin D. Kilbourne, a renowned New York virologist who served on the advisory committee, which voted 13-4 against Relenza.

Glaxo Wellcome had presented the panel with data from three trials involving a total of 1,609 patients in Europe, Australia and North America. By Glaxo Wellcome’s analysis, the drug shaved up to two and a half days off a seven-day flu if the medication were taken within two days of the appearance of flu symptoms.

But there were some major catches. In the North American study, by far the largest, Relenza reduced the average duration of a flu case by only a day. When the FDA’s statistician got through with the data, it looked more like half a day. And Kilbourne — a scientist who is enthusiastic about the eventual deployment of an anti-neurominidase drug — found even that misleading.

“In terms of the acute symptoms — incapacitation and fever — flu
is a three- to four-day disease,” he says. “So to say this drug reduces a seven-day illness to a six-day illness, when the symptoms at the end are rather trivial, is to make somewhat unfair claims of efficacy.”

Furthermore, how many people could be expected to get to a doctor,
get proper diagnosis of flu, and get the drug within the relevant 48 hours after the first symptoms? “Depressingly few,” says Alan Sanders, an infectious disease specialist in Albany, N.Y.

Much to the astonishment of Kilbourne and other scientists, the FDA in July decided to ignore its panel’s advice and approve the drug anyway. The July 26 approval memorandum from Heidi M. Jolson, director of the FDA’s division of antiviral drug products, makes it clear she wasn’t particularly impressed by Relenza. Glaxo’s U.S./Canada study “was inconclusive in providing definitive evidence of efficacy,” she writes.

Despite this, FDA officials seem to have given the thumbs up to Relenza and
Tamiflu — which is even newer and more untested than Relenza — for
another public health reason: The next time there’s a flu pandemic, we need to have tested drugs available. And the only way to test these particular drugs is to give them a wider public outing than the clinical trials permitted.

Relenza, writes Jolson, “will offer an alternative therapeutic approach for an important public health problem.” Adds CDC flu honcho Nancy Cox, in an Oct. 28 editorial in the New England Journal of Medicine, “Patients, clinicians and the public health community alike will be fortunate to have these new drugs. Now we must determine how they may best be used.”

“I suppose the FDA felt there were so few drugs available that any drug was better than nothing,” comments Kilbourne. “I don’t think that’s an adequate answer.”

One issue the advisory panel agreed upon, which surely played a role in the FDA’s decision, was the good safety profile of Relenza. (Although Relenza did appear to temporarily reduce the lung function of some asthmatics who used it, the company has put a warning label on its product, a dry powder inhaled via a spaceship-shaped device.)
The FDA could more easily make guinea pigs of the public knowing that the drug was harmless — even if it was also worthless.

That said, early tests have shown that Tamiflu, which comes in a pill, produced vomiting twice as often as the placebo.

Still, the drugs will certainly work for some people. The most encouraging
use, though not the one listed on the drugs’ labels, is as prophylaxis for
family members of a flu patient. And the new medications may have the side benefit of lowering antibiotic use, which always increases in flu season and which contributes to the harrowing threat of antibiotic resistance.

“By treating people with something that makes them feel better a day or two earlier we’ll be prescribing fewer antibiotics,” predicts Sanders, the infectious disease specialist. “People want to leave the doctor’s office with something and in this country that something is usually antibiotics. Now the doctors have something in their armamentarium specifically for flu.”

And what about the problem of viral resistance? No one seems particularly worried about it — yet. The flu virus is constantly evolving anyway, and there’s no indication the neuraminidase inhibitors will promote the kind of radical genetic shift that would produce a pandemic virus.

“I don’t see a problem of resistance with Relenza,” says Kilbourne with a chuckle. “Most of the viruses are apparently fit enough to resist it already.”

The next pandemic is what really worries flu scientists. They know it’s coming; they don’t know when, or from where.

In 1976, in an episode recounted in New York Times reporter Gina Kolata’s new book, “Flu,” a healthy soldier’s death at Fort Dix, N.J., sent government officials into the panicked conviction they had a pandemic on their hands — from a flu virus that originated in pigs.

They began a massive vaccination campaign for a swine flu epidemic that
never came. It ended up also costing the government billions of dollars in payments to people who believed the shots gave them a crippling autoimmune disorder called Guillain-Barré syndrome.

Let’s hope the FDA’s apparently hasty approval of Relenza doesn’t have
such a sad ending.

Arthur Allen writes on health, science and other issues for Salon. He lives in Washington.

More Related Stories

Featured Slide Shows

  • Share on Twitter
  • Share on Facebook
  • 1 of 11
  • Close
  • Fullscreen
  • Thumbnails

    Ten spectacular graphic novels from 2014

    Beautiful Darkness by Fabien Vehlmann & Kerascoët
    Kerascoët's lovely, delicate pen-and-watercolor art -- all intricate botanicals, big eyes and flowing hair -- gives this fairy story a deceptively pretty finish. You find out quickly, however, that these are the heartless and heedless fairies of folk legend, not the sentimental sprites beloved by the Victorians and Disney fans. A host of tiny hominid creatures must learn to survive in the forest after fleeing their former home -- a little girl who lies dead in the woods. The main character, Aurora, tries to organize the group into a community, but most of her cohort is too capricious, lazy and selfish to participate for long. There's no real moral to this story, which is refreshing in itself, beyond the perpetual lessons that life is hard and you have to be careful whom you trust. Never has ugly truth been given a prettier face.

    Ten spectacular graphic novels from 2014

    Climate Changed: A Personal Journey Through the Science by Philippe Squarzoni
    Squarzoni is a French cartoonist who makes nonfiction graphic novels about contemporary issues and politics. While finishing up a book about France under Jacques Chirac, he realized that when it came to environmental policy, he didn't know what he was talking about. "Climate Changed" is the result of his efforts to understand what has been happening to the planet, a striking combination of memoir and data that ruminates on a notoriously elusive, difficult and even imponderable subject. Panels of talking heads dispensing information (or Squarzoni discussing the issues with his partner) are juxtaposed with detailed and meticulous yet lyrical scenes from the author's childhood, the countryside where he takes a holiday and a visit to New York. He uses his own unreachable past as a way to grasp the imminent transformation of the Earth. The result is both enlightening and unexpectedly moving.

    Ten spectacular graphic novels from 2014

    Here by Richard McGuire
    A six-page version of this innovative work by a regular contributor to the New Yorker first appeared in RAW magazine 25 years ago. Each two-page spread depicts a single place, sometimes occupied by a corner of a room, over the course of 4 billion years. The oldest image is a blur of pink and purple gases; others depict hazmat-suited explorers from 300 years in the future. Inset images show the changing decor and inhabitants of the house throughout its existence: family photos, quarrels, kids in Halloween costumes, a woman reading a book, a cat walking across the floor. The cumulative effect is serene and ravishing, an intimation of the immensity of time and the wonder embodied in the humblest things.

    Ten spectacular graphic novels from 2014

    Kill My Mother by Jules Feiffer
    The legendary Pulitzer Prize-winning cartoonist delivers his debut graphic novel at 85, a deliriously over-the-top blend of classic movie noir and melodrama that roams from chiaroscuro Bay City to Hollywood to a USO gig in the Pacific theater of World War II. There's a burnt-out drunk of a private eye, but the story is soon commandeered by a multigenerational collection of ferocious women, including a mysterious chanteuse who never speaks, a radio comedy writer who makes a childhood friend the butt of a hit series and a ruthless dame intent on making her whiny coward of a husband into a star. There are disguises, musical numbers and plenty of gunfights, but the drawing is the main attraction. Nobody convey's bodies in motion more thrillingly than Feiffer, whether they're dancing, running or duking it out. The kid has promise.

    Ten spectacular graphic novels from 2014

    The Motherless Oven by Rob Davis
    This is a weird one, but in the nervy surreal way that word-playful novels like "A Clockwork Orange" or "Ulysses" are weird. The main character, a teenage schoolboy named Scarper Lee, lives in a world where it rains knives and people make their own parents, contraptions that can be anything from a tiny figurine stashable in a pocket to biomorphic boiler-like entities that seem to have escaped from Dr. Seuss' nightmares. Their homes are crammed with gadgets they call gods and instead of TV they watch a hulu-hoop-size wheel of repeating images that changes with the day of the week. They also know their own "death day," and Scarper's is coming up fast. Maybe that's why he runs off with the new girl at school, a real troublemaker, and the obscurely dysfunctional Castro, whose mother is a cageful of talking parakeets. A solid towline of teenage angst holds this manically inventive vision together, and proves that some graphic novels can rival the text-only kind at their own game.

    Ten spectacular graphic novels from 2014

    NOBROW 9: It's Oh So Quiet
    For each issue, the anthology magazine put out by this adventurous U.K.-based publisher of independent graphic design, illustration and comics gives 45 artists a four-color palette and a theme. In the ninth issue, the theme is silence, and the results are magnificent and full of surprises. The comics, each told in images only, range from atmospheric to trippy to jokey to melancholy to epic to creepy. But the two-page illustrations are even more powerful, even if it's not always easy to see how they pertain to the overall concept of silence. Well, except perhaps for the fact that so many of them left me utterly dumbstruck with visual delight.

    Ten spectacular graphic novels from 2014

    Over Easy by Mimi Pond
    When Pond was a broke art student in the 1970s, she took a job at a neighborhood breakfast spot in Oakland, a place with good food, splendid coffee and an endlessly entertaining crew of short-order cooks, waitresses, dishwashers and regular customers. This graphic memoir, influenced by the work of Pond's friend, Alison Bechdel, captures the funky ethos of the time, when hippies, punks and disco aficionados mingled in a Bay Area at the height of its eccentricity. The staff of the Imperial Cafe were forever swapping wisecracks and hopping in and out of each other's beds, which makes them more or less like every restaurant team in history. There's an intoxicating esprit de corps to a well-run everyday joint like the Imperial Cafe, and never has the delight in being part of it been more winningly portrayed.

    Ten spectacular graphic novels from 2014

    The Shadow Hero by Gene Luen Yang and Sonny Liew
    You don't have to be a superhero fan to be utterly charmed by Yang and Liew's revival of a little-known character created in the 1940s by the cartoonist Chu Hing. This version of the Green Turtle, however, is rich in characterization, comedy and luscious period detail from the Chinatown of "San Incendio" (a ringer for San Francisco). Hank, son of a mild-mannered grocer, would like to follow in his father's footsteps, but his restless mother (the book's best character and drawn with masterful nuance by Liew) has other ideas after her thrilling encounter with a superhero. Yang's story effortlessly folds pathos into humor without stooping to either slapstick or cheap "darkness." This is that rare tribute that far surpasses the thing it celebrates.

    Ten spectacular graphic novels from 2014

    Shoplifter by Michael Cho
    Corinna Park, former English major, works, unhappily, in a Toronto advertising agency. When the dissatisfaction of the past five years begins to oppress her, she lets off steam by pilfering magazines from a local convenience store. Cho's moody character study is as much about city life as it is about Corinna. He depicts her falling asleep in front of the TV in her condo, brooding on the subway, roaming the crowded streets after a budding romance goes awry. Like a great short story, this is a simple tale of a young woman figuring out how to get her life back, but if feels as if it contains so much of contemporary existence -- its comforts, its loneliness, its self-deceptions -- suspended in wintery amber.

    Ten spectacular graphic novels from 2014

    Through the Woods by Emily Carroll
    This collection of archetypal horror, fairy and ghost stories, all about young girls, comes lushly decked in Carroll's inky black, snowy white and blood-scarlet art. A young bride hears her predecessor's bones singing from under the floorboards, two friends make the mistake of pretending to summon the spirits of the dead, a family of orphaned siblings disappears one by one into the winter nights. Carroll's color-saturated images can be jagged, ornate and gruesome, but she also knows how to chill with absence, shadows and a single staring eye. Literary readers who cherish the work of Kelly Link or the late Angela Carter's collection, "The Bloody Chamber," will adore the violent beauty on these pages.

  • Recent Slide Shows

Comments

0 Comments

Comment Preview

Your name will appear as username ( settings | log out )

You may use these HTML tags and attributes: <a href=""> <b> <em> <strong> <i> <blockquote>